Stockscreener 앱 받기
3.03
1.00%
0.03
시간 외 거래:
3.02
-0.010
-0.33%
전일 마감가:
$3.00
열려 있는:
$3
하루 거래량:
47,269
Relative Volume:
0.10
시가총액:
$6.49M
수익:
$743.00K
순이익/손실:
$-7.63M
주가수익비율:
-0.2434
EPS:
-12.4498
순현금흐름:
-
1주 성능:
+7.45%
1개월 성능:
-9.82%
6개월 성능:
-44.63%
1년 성능:
-85.57%
1일 변동 폭
$2.9091
$3.18
1주일 범위
$2.84
$3.18
52주 변동 폭
$2.82
$21.80
캔 파이트 바이오파마 Stock (CANF) Company Profile
명칭
Can-Fite Biopharma Ltd ADR
전화
972 3 924 1114
주소
10 Bareket Street, Kiryat Matalon PO Box 7537, Petah-Tikva
Compare CANF vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CANF
Can-Fite Biopharma Ltd ADR
|
3.03 | 6.41M | 743.00K | -7.63M | 0 | -12.45 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
캔 파이트 바이오파마 Stock (CANF) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2017-08-11 | 개시 | Maxim Group | Buy |
| 2016-10-19 | 재개 | ROTH Capital | Buy |
| 2016-08-29 | 재개 | Rodman & Renshaw | Buy |
| 2015-11-30 | 재확인 | H.C. Wainwright | Buy |
| 2015-03-31 | 재확인 | H.C. Wainwright | Buy |
| 2015-03-30 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2014-12-29 | 재확인 | ROTH Capital | Buy |
| 2014-11-18 | 개시 | H.C. Wainwright | Buy |
모두보기
캔 파이트 바이오파마 주식(CANF)의 최신 뉴스
CANF Stock Price, Quote & Chart - ChartMill
CANF Technical Analysis | Trend, Signals & Chart Patterns | CAN FITE BIOPHARMA LTD-ADR (NYSEARCA:CANF) - ChartMill
CANF - Finviz
CANF Stock Chart | CAN FITE BIOPHARMA LTD-ADR (NYSEARCA:CANF) - ChartMill
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market - Sahm
Can Fite Biopharma stock rises on osteoarthritis study publication By Investing.com - Investing.com South Africa
What Can-Fite Bio (CANF) is doing that could pay off big later (Rallies Strongly) 2026-05-08Long Term Investing - newser.com
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months - ChartMill
CANF Ownership | CAN FITE BIOPHARMA LTD-ADR (NYSEARCA:CANF) - ChartMill
Can Fite Biopharma Ltd ADR (CANF) - Minichart
The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight - GlobeNewswire Inc.
Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026 - ChartMill
Can-Fite BioPharma (CANF) outlines clinical pipeline, cash runway and key risks - Stock Titan
Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient - ChartMill
Can-Fite reports 2025 loss, raises $4.3 million in March - Investing.com
CANF Earnings History & Surprises | EPS & Revenue Results | CAN FITE BIOPHARMA LTD-ADR (NYSEARCA:CANF) - ChartMill
Can-Fite receives Israeli patent for obesity treatment use - Investing.com
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance - Sahm
12 Health Care Stocks Moving In Wednesday's After-Market Session - Sahm
CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data - Finviz
Can-Fite BioPharma raises $4M through warrant exercise - Investing.com
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds - ChartMill
Gapping stocks in Wednesday's session - ChartMill
Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy - ChartMill
Can Fite Biopharma stock rises after patient success with liver treatment - Investing.com
Can-Fite BioPharma schedules special shareholder meeting as NYSE American issues non-compliance notice - Investing.com
Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson - Sahm
Published on: 2026-01-10 23:44:28 - ulpravda.ru
Why Aptevo Therapeutics Shares Are Trading Lower By Around 38%? Here Are Other Stocks Moving In Friday's Mid-Day Session - Benzinga
Can Fite Biopharma stock soars on Brazil patent grant for sexual dysfunction - Investing.com
Can Fite Biopharma stock soars on Brazil patent grant for sexual dysfunction By Investing.com - Investing.com South Africa
Curious about the most active stocks on Friday? - ChartMill
Can-Fite Biopharma Ltd Sponsored ADR (Israel) (NYSE:CANF) Stock Quote - FinancialContent
Can-Fite BioPharma stock rating downgraded to Hold by D. Boral Capital - Investing.com South Africa
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Sahm
Why Multi Ways Holdings Shares Are Trading Higher By Around 60%; Here Are 20 Stocks Moving Premarket - Sahm
These stocks that are showing activity before the opening bell on Wednesday. - ChartMill
UiPath, Ramaco Resources And 3 Stocks To Watch Heading Into Wednesday - Sahm
NYSE AMEX Composite Index (XAX) - Investing.com Canada
Can Fite Biopharma stock tumbles after announcing 1-for-3,000 reverse split By Investing.com - Investing.com South Africa
Can Fite Biopharma stock tumbles after announcing 1-for-3,000 reverse split - Investing.com India
Can-Fite BioPharma announces 1-for-3,000 reverse stock split - Investing.com
Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change - Sahm
EBITDA per share of Can-Fite BioPharma Ltd. Sponsored ADR – AMEX:CANF - TradingView — Track All Markets
Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference - Sahm
Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 Conference - The Manila Times
Let's uncover which stocks are experiencing notable gaps during today's session. - ChartMill
Stock Ratings | Morgan Stanley maintained its "neutral" rating on Palantir Technologies (PLTR) and raised its price target from $155 to $205. - Sahm
Can-Fite reaches 50% enrollment milestone in pancreatic cancer trial - Investing.com
Top movers in Monday's session - ChartMill
캔 파이트 바이오파마 (CANF) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):